Also known as: Ebola
Moderna posted a narrower-than-expected Q2 loss, with mFLUSIVA awaiting an FDA decision and a Phase 3 norovirus trial missing early success criteria. It reaffirmed 2026 revenue growth and cash guidance.
The Bundibugyo Ebola outbreak in the DRC has surpassed 3,200 cases and 1,400 deaths, becoming the fastest-spreading Ebola outbreak ever. The first-ever Bundibugyo-specific vaccine trial has begun at Oxford, while healthcare workers at the epicenter have gone on strike over unpaid wages. The WHO has declared the outbreak a global health emergency.
WHO has launched the PARTNERS clinical trial testing MBP134 and remdesivir for Bundibugyo virus disease in the DRC. Advisers recommend limiting all candidate Ebola drugs to clinical trials. The outbreak has caused 1,792 confirmed cases and 625 deaths as of July 9.
The Trump administration barred NIAID officials from WHO meetings, reclaimed $600M from four states, and faced a Senate report showing drug prices rising despite deals. New drugs average $353K a year.
Ebola Virus Disease remains a public health concern due to its high fatality rate. A new outbreak has been confirmed in Congo’s Ituri province, while early treatment and approved monoclonal antibodies can enhance survival.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05992480 |
REVIVE (Response to the Ebola Virus Vaccine) |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT04186000 |
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola |
COMPLETED | PHASE2 |
